KRAS mutations detection methodology: from RFLP to CRISPR/Cas based methods
- PMID: 39367162
- DOI: 10.1007/s10142-024-01421-z
KRAS mutations detection methodology: from RFLP to CRISPR/Cas based methods
Abstract
In personalized cancer medicine, the identification of KRAS mutations is essential for making treatment decisions and improving patient outcomes. This work presents a comprehensive review of the current approaches for detection of KRAS mutations in different cancers. We highlight the value of fast and reliable KRAS mutations discovery and the effectiveness of molecular testing for selecting individuals who might benefit from targeted therapy. We provide an overview of various methods and tools available for detecting KRAS mutations, such as digital droplet PCR, next-generation sequencing (NGS), and polymerase chain reaction (PCR). We also address the difficulties and limitations in the identification of KRAS mutations, namely tumor heterogeneity and the emergence of resistance mechanisms. This article aims to guide clinicians in KRAS mutation identification.
Keywords: KRAS; Molecular diagnostic methods; Personalized cancer medicine; RAS family.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Bender G, Yamaci F, R., Taneri B (2021) CRISPR and KRAS: a match yet to be made. J Biomed Sci 28(1):77. https://doi.org/10.1186/s12929-021-00772-0 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
